Literature DB >> 10548144

The safety of adenosine pharmacologic stress testing in patients with first-degree atrioventricular block in the presence and absence of atrioventricular blocking medications.

G S Alkoutami1, W C Reeves, A Movahed.   

Abstract

BACKGROUND: Pharmacologic stress testing in conjunction with radionuclide myocardial perfusion imaging may be used in the diagnosis of coronary artery disease and risk assessment. Adenosine can cause atrioventricular nodal (AV) block during infusion. In this study, we evaluated whether patients with baseline first-degree AV block could safely undergo adenosine stress testing. METHODS AND
RESULTS: We evaluated the frequency of second- and third-degree AV block in patients with baseline first-degree AV block during adenosine stress testing, in the presence and absence of AV blocking medications (digitalis, beta-blockers, diltiazem, verapamil). Six hundred consecutive patients underwent pharmacologic stress myocardial perfusion imaging with adenosine infusion at 140 microg/kg/min for 6 minutes. A total of 43 patients (7.16%) had baseline first-degree AV block (PR interval > 200 msec), and 557 patients had a baseline PR interval < 200 msec. Twenty-one of the 43 patients (48.8 %) had further prolongation of PR interval > 240 msec, compared with 58 of 557 patients (10.4%) in the control group (P < .0001). In 16 of the 43 patients (37.3 %), second-degree AV block developed, compared with 45 of 557 patients (8.0 %) in the control group (P < .0001). In 6 of the 43 patients (13.9%), third-degree AV block developed, compared with 6 of 557 patients (1.0%) in the control group (P < .0001). All types of AV block were short duration and were not associated with any specific symptoms. None of these episodes required specific treatment. The presence of AV blocking medications (digitalis, beta-blockers, diltiazem, verapamil) did not increase the incidence of AV block during adenosine infusion.
CONCLUSION: In patients with baseline PR interval of more than 200 msec, the frequency of second- and third-degree AV block during adenosine stress testing was significantly higher than in patients with a normal baseline PR interval. AV blocking medications did not increase the incidence of second- and third-degree AV block during adenosine stress testing. We conclude that it is safe to perform adenosine pharmacologic stress testing in patients with baseline PR prolongation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10548144     DOI: 10.1016/s1071-3581(99)90021-1

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   5.952


  6 in total

Review 1.  The cardiac effects of adenosine.

Authors:  L Belardinelli; J Linden; R M Berne
Journal:  Prog Cardiovasc Dis       Date:  1989 Jul-Aug       Impact factor: 8.194

Review 2.  Pharmacologic stress testing: mechanism of action, hemodynamic responses, and results in detection of coronary artery disease.

Authors:  A S Iskandrian; M S Verani; J Heo
Journal:  J Nucl Cardiol       Date:  1994 Jan-Feb       Impact factor: 5.952

3.  Safety profile of adenosine stress perfusion imaging: results from the Adenoscan Multicenter Trial Registry.

Authors:  M D Cerqueira; M S Verani; M Schwaiger; J Heo; A S Iskandrian
Journal:  J Am Coll Cardiol       Date:  1994-02       Impact factor: 24.094

4.  Arbutamine stress thallium-201 single-photon emission computed tomography using a computerized closed-loop delivery system. Multicenter trial for evaluation of safety and diagnostic accuracy. The International Arbutamine Study Group.

Authors:  H Kiat; A S Iskandrian; B J Villegas; M R Starling; D S Berman
Journal:  J Am Coll Cardiol       Date:  1995-11-01       Impact factor: 24.094

5.  Dobutamine thallium-201 tomography for evaluating patients with suspected coronary artery disease unable to undergo exercise or vasodilator pharmacologic stress testing.

Authors:  J T Hays; J J Mahmarian; A J Cochran; M S Verani
Journal:  J Am Coll Cardiol       Date:  1993-06       Impact factor: 24.094

6.  Diagnosis of coronary artery disease by controlled coronary vasodilation with adenosine and thallium-201 scintigraphy in patients unable to exercise.

Authors:  M S Verani; J J Mahmarian; J B Hixson; T M Boyce; R A Staudacher
Journal:  Circulation       Date:  1990-07       Impact factor: 29.690

  6 in total
  6 in total

1.  Vasodilator stress agents for myocardial perfusion imaging.

Authors:  Rayan Saab; Fadi G Hage
Journal:  J Nucl Cardiol       Date:  2016-02-02       Impact factor: 5.952

2.  Arrhythmias in vasodilator stress testing.

Authors:  Rajeeve Subbiah; Pravin V Patil
Journal:  J Nucl Cardiol       Date:  2016-02-02       Impact factor: 5.952

3.  Adenosine stress myocardial perfusion imaging in octogenarians: Safety, tolerability, and long-term prognostic implications of hemodynamic response and SPECT-related variables.

Authors:  Athanasios Katsikis; Athanasios Theodorakos; Spyridon Papaioannou; Antonios Kalkinis; Genovefa Kolovou; Konstantinos Konstantinou; Maria Koutelou
Journal:  J Nucl Cardiol       Date:  2017-04-26       Impact factor: 5.952

4.  Incidence of atrioventricular block with vasodilator stress SPECT: A meta-analysis.

Authors:  Efstathia Andrikopoulou; Charity J Morgan; Lizbeth Brice; Navkaranbir S Bajaj; Harish Doppalapudi; Ami E Iskandrian; Fadi G Hage
Journal:  J Nucl Cardiol       Date:  2017-10-17       Impact factor: 5.952

5.  Safety of adenosine pharmacologic stress myocardial perfusion imaging in orthotopic cardiac transplant recipients: a single center experience of 102 transplant patients.

Authors:  Mouaz H Al-Mallah; Muhammad Arida; Enrique Garcia-Sayan; Chafik Assal; Gino Tapia Zegarra; Barbara Czerska; Karthik Ananthasubramaniam
Journal:  Int J Cardiovasc Imaging       Date:  2010-11-19       Impact factor: 2.357

6.  Electrocardiographic profile of adenosine pharmacological stress testing.

Authors:  Hao Sun; Yueqin Tian; Lihui Zheng; Qingrong Pan; Boqia Xie
Journal:  Exp Ther Med       Date:  2015-02-09       Impact factor: 2.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.